发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
Bispecific antibodies in NSCLC: immune reengineering to neutralize adaptive tumor resistance. 非小细胞肺癌的双特异性抗体：免疫重组以中和适应性肿瘤抵抗。
IF 21.6 1区 医学
Trends in cancer Pub Date : 2026-10-20 DOI: 10.1016/j.trecan.2026.09.010
Zetong Li, Haowei Wang, Meng Diao, Ruixuan Liu, Xinyao Wang, Anwen Xiong, Caicun Zhou, Zhuoran Tang
{"title":"Bispecific antibodies in NSCLC: immune reengineering to neutralize adaptive tumor resistance.","authors":"Zetong Li, Haowei Wang, Meng Diao, Ruixuan Liu, Xinyao Wang, Anwen Xiong, Caicun Zhou, Zhuoran Tang","doi":"10.1016/j.trecan.2026.09.010","DOIUrl":"https://doi.org/10.1016/j.trecan.2026.09.010","url":null,"abstract":"<p><p>Over the past few decades, the emergence of immunotherapy and single-target drugs has brought new promise to the treatment of non-small cell lung cancer (NSCLC). Yet the high heterogeneity of NSCLC leads to both primary and acquired resistance that neither sequential monotherapy nor empirical combinations can effectively overcome. In contrast to the conventional coadministration of two separate monoclonal antibodies, bispecific antibodies (BsAbs) feature a series of molecular engineering designs that confer inherent synergistic antitumor effects. We propose that a network pharmacology perspective can be adopted to understand the application of BsAbs in NSCLC and to guide their subsequent development.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":21.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The tumor macroenvironment as cancer metabolism's next frontier. 肿瘤宏观环境是癌症代谢的下一个前沿。
IF 21.6 1区 医学
Trends in cancer Pub Date : 2026-10-20 DOI: 10.1016/j.trecan.2026.09.007
Allison B Grenell, Joe L Rowles, Ronnie Fowle-Grider, Yin Cao, Leah P Shriver, Gary J Patti
{"title":"The tumor macroenvironment as cancer metabolism's next frontier.","authors":"Allison B Grenell, Joe L Rowles, Ronnie Fowle-Grider, Yin Cao, Leah P Shriver, Gary J Patti","doi":"10.1016/j.trecan.2026.09.007","DOIUrl":"https://doi.org/10.1016/j.trecan.2026.09.007","url":null,"abstract":"<p><p>The deregulated utilization of nutrients by tumors, first observed over a century ago, is recognized as a hallmark of cancer and continues to be exploited clinically to image neoplastic disease. Despite this historic focus on cancer cells and, more recently, their neighbors, metabolic reprogramming is not limited to the tumor microenvironment. Tumors also have the capacity to rewire the metabolism of cells throughout the body, including those at distant sites, often referred to as the tumor macroenvironment. Alterations in the metabolism of noncancerous tissues outside the local tumor ecosystem are gaining attention, but their origins and consequences remain incompletely defined. A deeper understanding of these changes may reveal previously unrecognized signatures of disease and unexplored opportunities for therapeutic intervention.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":21.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MAIT cells in gastrointestinal cancer: immunity to therapy. 胃肠道肿瘤中的MAIT细胞：对治疗的免疫。
IF 21.6 1区 医学
Trends in cancer Pub Date : 2026-10-19 DOI: 10.1016/j.trecan.2026.09.009
Yan-Ruide Li, Yuning Chen, Shelby Yeh, Thomas Yuen, Lili Yang
{"title":"MAIT cells in gastrointestinal cancer: immunity to therapy.","authors":"Yan-Ruide Li, Yuning Chen, Shelby Yeh, Thomas Yuen, Lili Yang","doi":"10.1016/j.trecan.2026.09.009","DOIUrl":"https://doi.org/10.1016/j.trecan.2026.09.009","url":null,"abstract":"<p><p>Mucosal-associated invariant T (MAIT) cells are emerging as important regulators of immunity in gastrointestinal (GI) cancers. Enriched in mucosal and hepatic tissues, MAIT cells recognize microbial-derived metabolites presented by MHC class I-related molecule (MR1) and rapidly exert effector functions, including cytokine production and cytotoxicity. Across GI malignancies, including hepatocellular carcinoma, cholangiocarcinoma, colorectal, gastric, pancreatic, and esophageal cancers, MAIT cells display context-dependent roles shaped by the tumor microenvironment, microbiome, and immune signaling pathways. While they can mediate antitumor immunity, they frequently exhibit functional exhaustion or adopt pro-tumorigenic phenotypes. Therapeutic strategies aim to enhance MAIT cell activity, reverse dysfunction, and integrate them into combinatorial immunotherapy approaches. Understanding MAIT cell biology may enable their exploitation as biomarkers and therapeutic targets in GI cancers.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":21.6,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging landscape of antibody-drug conjugates in lung cancer: a clinical review. 肺癌中抗体-药物结合物的新前景：临床综述。
IF 21.6 1区 医学
Trends in cancer Pub Date : 2026-10-13 DOI: 10.1016/j.trecan.2026.09.002
Henry Pickett, Javier Arias-Romero, Jeremy Fricke, Isa Mambetsariev, Neil Chen, Debora S Bruno, Matthew Lee, Arya Amini, Jyoti Malhotra, Ravi Salgia
{"title":"Emerging landscape of antibody-drug conjugates in lung cancer: a clinical review.","authors":"Henry Pickett, Javier Arias-Romero, Jeremy Fricke, Isa Mambetsariev, Neil Chen, Debora S Bruno, Matthew Lee, Arya Amini, Jyoti Malhotra, Ravi Salgia","doi":"10.1016/j.trecan.2026.09.002","DOIUrl":"https://doi.org/10.1016/j.trecan.2026.09.002","url":null,"abstract":"<p><p>Lung cancer is a heterogeneous disease, and while targeted therapies and immunotherapies have improved patient outcomes, 5-year overall survival remains poor at approximately 20%. Antibody-drug conjugates (ADCs) target tumors using a targeted antibody that delivers a cytotoxic payload with clinically proven antitumor activity, and over a dozen ADCs are under consideration for solid tumors. Recent clinical trial data in metastatic non-small cell lung cancer have led to FDA approval of three ADCs: trastuzumab deruxtecan for patients with human epidermal growth factor receptor 2-mutated disease, telisotuzumab vedotin for MET-overexpressing tumors, and datopotamab deruxtecan for patients with epidermal growth factor receptor-mutated disease. In this article, we review the trajectory of individual ADC targets in lung cancer, describe the latest clinical trial results, and discuss future innovations in ADC therapies and potential mechanisms of resistance.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":21.6,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protecting axonal mitochondria prevents chemotherapy-driven neuropathy. 保护轴突线粒体防止化疗驱动的神经病变。
IF 21.6 1区 医学
Trends in cancer Pub Date : 2026-10-08 DOI: 10.1016/j.trecan.2026.09.005
Lorenzo Galluzzi, Jorge Gómez-Deza
{"title":"Protecting axonal mitochondria prevents chemotherapy-driven neuropathy.","authors":"Lorenzo Galluzzi, Jorge Gómez-Deza","doi":"10.1016/j.trecan.2026.09.005","DOIUrl":"https://doi.org/10.1016/j.trecan.2026.09.005","url":null,"abstract":"<p><p>Peripheral neuropathy is a poorly understood yet extraordinarily relevant obstacle to the effective implementation of cytotoxic chemotherapy in patients with cancer. Recent findings from Heles et al. demonstrate that safe neuroactive molecules that promote mitochondrial fitness in axons effectively prevent peripheral neuropathy in preclinical tumor models, thereby supporting clinical translation.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":21.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancer of zeste homolog 2 links epigenetic plasticity to cholesterol metabolism. 趣味同源物2增强子将表观遗传可塑性与胆固醇代谢联系起来。
IF 21.6 1区 医学
Trends in cancer Pub Date : 2026-10-08 DOI: 10.1016/j.trecan.2026.09.006
Cheng Wang, Hongwen Zhu, Xiongjun Wang
{"title":"Enhancer of zeste homolog 2 links epigenetic plasticity to cholesterol metabolism.","authors":"Cheng Wang, Hongwen Zhu, Xiongjun Wang","doi":"10.1016/j.trecan.2026.09.006","DOIUrl":"https://doi.org/10.1016/j.trecan.2026.09.006","url":null,"abstract":"<p><p>Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of Polycomb repressive complex 2 (PRC2), which mediates transcriptional repression. Kim and colleagues uncover a PRC2-independent EZH2-sterol regulatory element-binding protein 2 (SREBP2) axis that drives cholesterol biosynthesis, revealing an epigenetic-metabolic vulnerability exploitable through targeted protein degradation.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":21.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision before incision: neoadjuvant tumor-agnostic therapies. 切口前精确：新辅助肿瘤不可知论治疗。
IF 21.6 1区 医学
Trends in cancer Pub Date : 2026-10-08 DOI: 10.1016/j.trecan.2026.09.001
Juliana Beal, Niamh Coleman, Jia Liu, Jason K Sicklick, Julian Bryan, Vivek Subbiah
{"title":"Precision before incision: neoadjuvant tumor-agnostic therapies.","authors":"Juliana Beal, Niamh Coleman, Jia Liu, Jason K Sicklick, Julian Bryan, Vivek Subbiah","doi":"10.1016/j.trecan.2026.09.001","DOIUrl":"https://doi.org/10.1016/j.trecan.2026.09.001","url":null,"abstract":"<p><p>The emergence of tumor-agnostic therapies has fundamentally transformed precision oncology. Traditionally developed and approved for metastatic disease, nine therapies spanning immunotherapy, targeted agents, and antibody-drug conjugates now demonstrate a compelling rationale for earlier deployment in the neoadjuvant setting. This review examines the paradigm shift from last-resort to first-consideration approaches. Key advantages of neoadjuvant, biomarker-guided therapy include intervention prior to the development of therapeutic resistance, optimal immune system engagement, and opportunities for organ preservation. Single-agent programmed cell death protein-1 blockade has achieved a 100% complete response rate in mismatch repair-deficient rectal cancer with preserved organ function. Neurotrophic tyrosine receptor kinase (NTRK), rearranged during transfection (RET), and B-Raf proto-oncogene serine/threonine kinase (BRAF) inhibitors have demonstrated substantial responses that enable curative-intent surgery across malignancies. As precision oncology matures, the neoadjuvant tumor-agnostic approach exemplifies optimized therapeutic sequencing, potentially improving patient outcomes and quality of life.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":21.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Host metabolism rewrites metastatic fate. 宿主代谢改写了转移的命运。
IF 21.6 1区 医学
Trends in cancer Pub Date : 2026-10-01 Epub Date: 2026-09-03 DOI: 10.1016/j.trecan.2026.08.004
Zihan Qiu, Xinyu Li, Pengfei Xu
{"title":"Host metabolism rewrites metastatic fate.","authors":"Zihan Qiu, Xinyu Li, Pengfei Xu","doi":"10.1016/j.trecan.2026.08.004","DOIUrl":"10.1016/j.trecan.2026.08.004","url":null,"abstract":"<p><p>Metastatic heterogeneity has traditionally been explained by tumor-intrinsic evolution. A recent study by Peng-Winkler et al. challenges this paradigm by demonstrating that hepatic steatosis instructs colorectal cancer liver metastasis through fatty acid-dependent myelocytomatosis oncogene protein (MYC) activation. These findings identify host metabolism as an independent determinant of metastatic fate and suggest that precision oncology should extend beyond tumor genomics.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"895-897"},"PeriodicalIF":21.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148881960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accelerating rare cancer research: a Zebrafish-First Triage Strategy. 加速罕见癌症研究：斑马鱼优先分类策略。
IF 21.6 1区 医学
Trends in cancer Pub Date : 2026-10-01 Epub Date: 2026-08-28 DOI: 10.1016/j.trecan.2026.08.001
Bruno Lopes-Bastos, Ewa Snaar-Jagalska
{"title":"Accelerating rare cancer research: a Zebrafish-First Triage Strategy.","authors":"Bruno Lopes-Bastos, Ewa Snaar-Jagalska","doi":"10.1016/j.trecan.2026.08.001","DOIUrl":"10.1016/j.trecan.2026.08.001","url":null,"abstract":"<p><p>Rare cancers collectively account for approximately a quarter of diagnosed cancers. However, these tumors remain understudied due to research constraints, including underfunding, scarce samples, and reliance on resource-intensive mouse models. We propose a Zebrafish-First Triage Strategy to screen potential therapeutic targets before mammalian validation and accelerate research and drug development.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"898-901"},"PeriodicalIF":21.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148851307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma. 药物治疗：早期试验显示，trabectedin和低剂量伊立替康下调EWSR1::FLI1，并在晚期尤文氏肉瘤中具有临床活性。
IF 21.6 1区 医学
Trends in cancer Pub Date : 2026-10-01 Epub Date: 2026-08-21 DOI: 10.1016/j.trecan.2026.07.010
David S Shulman, Katherine A Janeway
{"title":"Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma.","authors":"David S Shulman, Katherine A Janeway","doi":"10.1016/j.trecan.2026.07.010","DOIUrl":"10.1016/j.trecan.2026.07.010","url":null,"abstract":"<p><p>Targeting transcription factor fusion-positive cancers has proven challenging for decades. In SARC037, Grohar et al. show that histology-specific dosing of trabectedin and low-dose irinotecan is active in advanced Ewing sarcoma and downregulates EWSR1::FLI1 activity.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"892-894"},"PeriodicalIF":21.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书